Previously, I had somewhat mixed feelings about Microsoft (NASDAQ:MSFT). I had acknowledged that while cloud was proving an area of strength for the company, it still remained to be seen as to whether the company could sufficiently drive earnings higher.
My previous article, titled “Microsoft: Investors Are Betting On The Cloud: Can The Stock Reach The Stars?”, illustrated my sentiment that Microsoft’s future growth potential rested heavily on how well the company can monetize cloud services going forward.
However, after a period of falling earnings which were in part due to a strong dollar and declining hardware sales depressing EPS growth, earnings have since rebounded very nicely, after the company’s cloud annualised run rate hit $13 billion for its first quarter:
learn about stock market: Douglas Dynamics Inc.(PLOW)
- [By Lisa Levin] Related PLOW 18 Biggest Mid-Day Losers For Tuesday 18 Biggest Mid-Day Gainers For Tuesday Douglas Dynamics Inc (PLOW) Chairman, President and CEO James L Janik Bought $59,5 of … (GuruFocus)
Related TIF Your Luxury Brands Earnings Cheat Sheet Guggenheim Initiates Coverage On 21 Retail Stocks Tiffany & Co: China Market Will Drive Earnings Growth For The Next Decade (Seeking Alpha)
It’s critical to know whether a stock you plan on buying has an ex-dividend status, because in case it does, the dividend would be paid out to the seller. The person who owns the stock on the ex-dividend date will be awarded the payment, which means that you’ll have to wait for the next dividend cycle to receive your first dividend payout from the company.
learn about stock market: Internet Gold Golden Lines Ltd.(IGLD)
- [By Lisa Levin]
In trading on Friday, telecommunications services shares fell by 0.43 percent. Meanwhile, top losers in the sector included Internet Gold Golden Lines Ltd (NASDAQ: IGLD), down 10 percent, and China Unicom (Hong Kong) Limited (ADR) (NYSE: CHU), down 3 percent.
learn about stock market: Valeant Pharmaceuticals International Inc(VRX)
- [By Ben Levisohn]
Valeant Pharmaceuticals International (VRX) has jumped 4.3% to $11.68 after activist investor ValueAct bought three million shares of the beaten-down specialty pharmaceutical company.
- [By Lisa Levin]
Healthcare shares rose by 1.68 percent in the US market on Thursday. Top gainers in the sector included Sangamo Therapeutics Inc (NASDAQ: SGMO), Valeant Pharmaceuticals Intl Inc (NYSE: VRX), and Tenet Healthcare Corp (NYSE: THC).
- [By Virendra Singh Chauhan]
Nvidia corporation stock shook off the bad performance from the last week, with a nearly 3% gain in the first trading session of this week. If you are wondering whether or not NVIDIA stock has turned the corner, a recent tweet from NVIDIA bear Andrew Left offers some answers. In late December, Citron’s Andrew Left issued a bearish NVDA call, calling a $90 bottom on the stock. Well, the famed short seller of Valeant (NYSE:VRX) fame, recently disclosed that he had covered its short position on NVIDIA. Given that Citron had originally called for a $90 price target, it appears likely that Citron thinks NVDA stock has bottomed out $10 above its original target.
- [By Chris Lange]
Valeant Pharmaceuticals International Inc. (NYSE: VRX) shares made a spectacular crash over the course of 2015 to 2017, and it looks like they now may be on the path to recovery. The stock ultimately responded positively when Valeant announced that its subsidiary Bausch + Lomb has begun distributing Vyzulta (latanoprostene bunod ophthalmic solution) for patients across the United States.
- [By Chris Lange]
Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares had an incredible gain on Tuesday after the company announced a licensing agreement with Valeant Pharmaceuticals International Inc. (NYSE: VRX). At one point in the day shares were up over 100%. According to the deal, Eyegate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the Eyegate II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.
learn about stock market: Nu Skin Enterprises Inc.(NUS)
- [By Craig Jones]
Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.
- [By Roberto Pedone]
Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.
Monday’s Volume: 2 million
Three-Month Average Volume: 900,802
Volume % Change: 85%
From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.
Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.
- [By Ben Levisohn]
Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:
“Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…
Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.
Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.
Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.
- [By Scott Rubin]
Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.
learn about stock market: Westinghouse Air Brake Technologies Corporation(WAB)
- [By WWW.MONEYSHOW.COM]
Westinghouse Air Brake Technologies Corporation (WAB) scores highly based on my Warren Buffett-based model, which is based on the book Buffettology, and also the Peter Lynch-inspired approach that uses the method outlined by Lynch in One Up on Wall Street.
learn about stock market: Coeur d’Alene Mines Corporation(CDE)
- [By Ben Levisohn]
Given revised commodity deck forecasts (particularly for Steel and Gold) and improved Balance Sheet health (Steels, Precious and Industrials Metals) we are upgrading our ratings on several stocks in our coverage. We generally favor companies that have already initiated specific self-help, have low-cost assets and are less exposed to China supply and demand dynamics. In Steels, we have increased our rating from Hold to Buy on Nucor (NUE) and from Sell to Hold on US Steel. We have also upgraded Kinross Gold (KGC) to a Hold on valuation…On higher-than-peer valuations, we reiterate Sell-rated Coeur Mining (CDE), Franco-Nevada (FNV), Goldcorp (GG), Teck Resources (TCK) and highly leveraged AK Steel given preference to issue further equity if possible.
- [By Ben Levisohn]
Deutsche Bank’s Jorge Beristain and Chris Terry released their earnings preview for the gold miners–including Barrick Gold (ABX), Goldcorp (GG), Franco-Nevada (FNV), and Coeur Mining (CDE)–and conclude that only one gold miner deserves a Buy rating: Newmont Mining (NEM). They explain why:
- [By Manikandan Raman]
Citing bullish outlook on silver prices, Peter Bures of Canaccord Genuity has started coverage of four silver producers: Pan American Silver Corp. (USA) (NASDAQ: PAAS), Coeur Mining Inc (NYSE: CDE), Hecla Mining Company (NYSE: HL), and Endeavour Silver Corp (NYSE: EXK). The brokerage also assumed coverage of Fortuna Silver Mines Inc (NYSE: FSM) with a Buy rating.
- [By Dan Caplinger]
Still, some stocks managed to buck the negative sentiment on Tuesday, and Sears Holdings (NASDAQ:SHLD), Plug Power (NASDAQ:PLUG) and Coeur Mining (NYSE:CDE) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.